EXPERT CALL: INNOVATION IN THE RENAL CARE CONTINUUM

Dr. Olaf Schermeier
September 20, 2021 | Virtual
Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy or might not even be anticipated. The Company has based these forward-looking statements on current estimates and assumptions which we believe are reasonable and which are made to the best of our knowledge. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA’s (FMC AG & Co. KGaA) Annual Report on Form 20-F under the heading “Forward-Looking Statements” and under the headings in that report referred to therein, and in FMC AG & Co. KGaA’s other reports filed with the Securities and Exchange Commission (SEC) and the Frankurt Stock Exchange (Frankfurter Wertpapierbörse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in Euro if not mentioned otherwise.
INNOVATION BASED ON OUR CORPORATE STRATEGY

RENAL CARE CONTINUUM
Dialysis Business, Value Based Care models, expansion along the renal patient journey to further enhance patient experience
Expand product portfolio and establish digital care models

COMPLEMENTARY ASSETS
Leverage core competencies for additional medical value creation
New patient-focused therapy offerings in renal care and beyond

CRITICAL CARE
Extracorporeal blood treatments and respiratory solutions
Xenios and NxStage Critical Care solutions to further broaden the critical care portfolio

WE LEVERAGE OUR DEEP TECHNOLOGY AND THERAPY EXPERTISE WITH A VERTICALLY INTEGRATED, USER CENTRIC, DIGITAL AND AGILE ENVIRONMENT TO REMAIN THE LEADER IN COMPREHENSIVE RENAL CARE
ADDRESSING CHALLENGES ALONGSIDE THE ENTIRE RENAL CARE CONTINUUM

- Preventing and delaying CKD progression
- Providing adequate diagnosis and tailored therapies
- Individualizing disease management

- Improving quality of life and therapy outcomes
- Providing affordable, safe and easy to use therapy systems
- Improving patient compliance and monitoring

- Reducing cost of care while improving therapy outcomes
- Enabling personalized care management and prescription of drugs

- Addressing global organ shortage
- Enhancing the lifetime of transplants
### EARLY DETECTION AND PERSONALIZED THERAPY ARE KEY

**CKD 3B-5:**
About 15% of U.S. adults have CKD – 9 of 10 are not aware of their disease*  

<table>
<thead>
<tr>
<th>EARLY CKD DETECTION</th>
<th>PERSONALIZED CKD MANAGEMENT</th>
<th>DELAY CKD 3B-5 PROGRESSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strategic investments in health monitoring platforms, cardiorenal technologies and diagnostic tools for early CKD identification and intervention</td>
<td>Leveraging therapy and health data pools providing individualized comorbidity management and personalized treatment</td>
<td>Regenerative medicine and new therapy approaches to treat and delay CKD 3B-5 progression</td>
</tr>
</tbody>
</table>

---

1 Source: Centers for Disease Control & Prevention | Chronic Kidney Disease in the United States, 2021

---

### VALUE CREATION

- Leading position to leverage new business models and revenue streams, establish highly profitable markets and at the same time provide best possible care
- Complementary approach to become the most comprehensive provider in renal care across the entire Renal Care Continuum
- Growing market segments also beyond dialysis allows to expand core segments
### PROVIDING NEXT GENERATION & AFFORDABLE HOME THERAPY SYSTEMS TO IMPROVE QUALITY OF LIFE

**HOME:**
Out of 3.6M dialysis patients globally, increasing number of patients undergo dialysis treatments at home\(^1\)

---

**IMPROVED QUALITY OF LIFE**

Next generation therapy systems for home therapies enabling data analytics and improved treatment outcomes

**AFFORDABLE HOME THERAPIES**

Affordable, reliable and easy to use home dialysis systems making dialysis treatments affordable for everyone

**CONNECTED HOME ENVIRONMENT**

Fully connected home environment enabling artificial Intelligence (AI), machine learning & predictive models to enhance quality of care

---

**VALUE CREATION**

- Seamless, simplified and easy to use next generation home therapy systems to improve the quality of life of patients
- Reliable, affordable and digitally enabled PD therapy system entering value segments and untapped markets
- Kinexus: Secure and cloud-based solution connecting patients and clinicians supports new “pay for service” business models

---

\(^1\) Source: Fresenius Medical Care
CONNECTED HOME ENVIRONMENT ENABLES PERSONALIZED CARE AND ADDITIONAL REVENUE STREAMS

HOME:
OUT OF 3.6M DIALYSIS PATIENTS GLOBALLY, INCREASING NUMBER OF PATIENTS UNDERGO DIALYSIS TREATMENTS AT HOME\(^1\)

<table>
<thead>
<tr>
<th>ENABLING CONNECTIVITY</th>
<th>Closing the gap between home patients and clinicians</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATA SECURITY &amp; PRIVACY</td>
<td>Applying highest standards to protect data and privacy of the patients</td>
</tr>
<tr>
<td>CLOUD ARCHITECTURE</td>
<td>Enabling data analytics, machine learning, artificial intelligence and predictive models</td>
</tr>
<tr>
<td>CREATING INSIGHTS</td>
<td>Providing better, actionable information to clinicians for better and personalized patient care</td>
</tr>
</tbody>
</table>

VALUE CREATION

- Creating a more personalized care environment to increase time on Peritoneal Dialysis in a home setting
- Minimalizing patient's self-management effort by automated data transfer and reduced reliance on paper flow sheets
- Timely intervention: with ongoing access to treatment data, clinicians can quickly adjust therapy settings to keep patients on track

\(^1\) Source: Fresenius Medical Care
# PERSONALIZED PRESCRIPTION AND PLATFORM TECHNOLOGIES

## IN-CENTER:

MAJOR PROPORTION OF DIALYSIS PATIENT POPULATION RECEIVE HD TREATMENTS IN AN IN-CENTER SET-UP

### PERSONALIZED PRESCRIPTION

Mathematical models and virtual clinical trials for tailored prescription of drugs improving therapy outcomes while **reducing cost of care**

### GLOBAL HD PLATFORM

Reducing cost of ownership with new and globally available HD platforms

### IMPROVED HEMOCOMPATIBILITY

Transformative membrane surface technology to **improve hemocompatibility** and therapy outcomes

---

**VALUE CREATION**

**Cost Savings:**

- Substantially reducing costs by enabling saline free dialysis
- Reduction of therapy costs by reduced medication and personalized prescription
- Reduced hospitalization by improved quality of treatments

**Revenue:**

- Accessing untapped patient segments in developing countries

---

1 Source: Fresenius Medical Care
XENOTRANSPLANTATION HAS THE POTENTIAL TO SOLVE GLOBAL ORGAN SHORTAGE

**TRANSPLANT:** NEW SOURCES OF ORGANS ARE VITAL TO SUPPLEMENT THE ±21,000 KIDNEY ALLOGRAFTS DONATED AND TRANSPLANTED PER YEAR\(^1\) – XENO ORGANS A POTENTIAL SOLUTION

<table>
<thead>
<tr>
<th>95,633 ESRD PATIENTS</th>
<th>APPROX. 435,000 ESRD PATIENTS</th>
</tr>
</thead>
</table>

... in the U.S. are on the Kidney Transplant Waitlist

... in the U.S. are **NOT** on the waitlist for a kidney transplant\(^2\) but could be eligible for a xeno kidney transplant\(^3\)

---

**VALUE CREATION**

- Expanding FME's transplantation business to become the most comprehensive provider in renal care
- Establish new Product and Service business models around transplantation
- Prerequisite: xenotransplantation proves efficacy in humans

---

1 U.S. Department of Health & Human Services, [Organ Procurement & Transplantation Network](https://optn.transplant.hrsa.gov) | 2 U.S. Renal Data System. 2018 Annual Data Report, Volume 2 – ESRD, Section B, Table B.1 Prevalent Counts of Reported ESRD | 3 An estimated 30% of dialysis-dependent ESRD patients would not be considered eligible for either allo or xeno kidney transplant
ADRESSING NEEDS OF PERSONALIZED MEDICINE IN CRITICAL CARE

COVID-19 & ACUTE KIDNEY INJURY: A QUARTER OF PATIENTS HOSPITALIZED WITH COVID-19 DEVELOP ACUTE KIDNEY INJURY

EXPANDING CRITICAL CARE

Next generation synchronized cardiac support systems for heart & lung therapies

GLOBALIZING ACUTE DIALYSIS THERAPIES

Improve therapies of patients in critical conditions globally by innovative CRRT systems with integrated intelligent software support

VALUE CREATION

- Expanding therapy offerings to patients in critical conditions globally
- Leveraging deep expertise in extracorporeal therapies to address patient segments beyond dialysis
- Further driving personalized care to address individual urgent needs of patients in critical conditions most efficiently

1 Pathophysiology of COVID-19-associated acute kidney injury (05 July 2021) | Matthieu Legrand, Samira Bell, Lui Forni, Michael Joannidis, Jay L. Koyner, Kathleen Liu & Vincenzo Cantaluppi
## EXTERNAL INNOVATION PIPELINE IN COMPLEMENTARY BUSINESS AREAS

<table>
<thead>
<tr>
<th>Area</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARDIO-VASCULAR</td>
<td>Develop solutions for the treatment of acute and chronic heart-failure, such as self-expanding miniaturized pumps for heart-failure patients</td>
</tr>
<tr>
<td>CARDIO-RENAL</td>
<td>Optical imaging solutions for non-invasive tissue and vascular assessment</td>
</tr>
<tr>
<td>AKI/SEPSIS</td>
<td>Extracorporeal blood filtration devices for removing pathogens and harmful substances from the blood</td>
</tr>
<tr>
<td>MENTAL HEALTH</td>
<td>Integrating behavioral care and medical care to improve health and total cost of care</td>
</tr>
<tr>
<td>VASCULAR</td>
<td>Address the unmet need of patients with difficult-to-treat peripheral artery disease (PAD)</td>
</tr>
<tr>
<td>HEALTH MOBILITY</td>
<td>Technology platform that simplifies medical transport, streamlines patient coordination and improves outcomes</td>
</tr>
</tbody>
</table>

### VALUE CREATION

- Leveraging FME expertise to expand therapy offering for our dialysis patients and beyond
- Upscaling external innovation and technologies with FME’s broad network and infrastructure
SUMMARY

INNOVATION CONTRIBUTES TO FRESENIUS MEDICAL CARE'S GROWTH AS AN INTRINSIC ELEMENT IN ALL AREAS OF OUR STRATEGY

RENAL CARE CONTINUUM

- As the leading and only vertically integrated provider, we understand the challenges and needs along the entire patient journey
- We are well-positioned to leverage market potential, reduce costs of care and at the same time further improve treatment quality

CRITICAL CARE

- We leverage our deep expertise to further expand and personalize therapy offerings to patients in critical conditions
- Address patient segments beyond dialysis

COMPLEMENTARY ASSETS

- Patient-focused approach
- External innovation pipeline to set milestones in non-renal products
Your questions are welcome!